New Swedish patent approval for Episurf Medical

Report this content

The Swedish patent office PRV has announced its intention to grant another Swedish patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “An implant for cartilage and/or bone repair”, is within the area of joint implant materials and implant features. 

“This is a patent covering combinations of implant bulk and coating materials, to protect specific features of Episurf’s Episealer® technology. We are happy for this first approval of this patent family”, says Katarina Flodström, COO, Episurf Medical.  


For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website:

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17.45 CEST on 22 June 2020.